Altimmune (ALT) Interest Expenses (2010 - 2026)
Altimmune (ALT) reported Interest Expenses of $1.1 million for Q1 2026, up 106700.0% year-over-year from N/an in Q1 2025, and up 21.92% on a QoQ basis from $876000.0 in Q4 2025.
Altimmune (ALT) has 17 years of Interest Expenses data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Interest Expenses rose 106700.0% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 29933.33% YoY) and the FY2025 annual result came in at $1.6 million, up 18077.78% from the prior year.
- Interest Expenses grew to $1.1 million in Q1 2026 per ALT's latest filing, from $876000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $1.1 million in Q1 2026 and bottomed at -$183000.0 in Q4 2022.
- The 5-year median for Interest Expenses is $6000.0 (2024), against an average of $162117.6.
- The widest annual swing landed in 2022, when Interest Expenses plunged 195.16%; it then surged 106700.0% in 2026.
- Tracing ALT's Interest Expenses over 5 years: stood at -$183000.0 in 2022, then surged by 101.09% to $2000.0 in 2023, then tumbled by 50.0% to $1000.0 in 2024, then surged by 87500.0% to $876000.0 in 2025, then climbed by 21.92% to $1.1 million in 2026.
- Per Business Quant, the three latest ALT Interest Expenses figures stand at $1.1 million (Q1 2026), $876000.0 (Q4 2025), and $495000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 876,000.00 |
| Dec 31, 2025 | 876,000.00 |
| Sep 30, 2025 | 495,000.00 |
| Sep 30, 2025 | 495,000.00 |
| Jun 30, 2025 | 264,000.00 |
| Jun 30, 2025 | 264,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 6,000.00 |
| Sep 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Sep 30, 2023 | 29,000.00 |
| Sep 30, 2023 | 29,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Dec 31, 2022 | -183,000.00 |
| Dec 31, 2022 | -183,000.00 |
| Sep 30, 2022 | 64,000.00 |
| Sep 30, 2022 | 64,000.00 |
| Jun 30, 2022 | 65,000.00 |
| Jun 30, 2022 | 65,000.00 |
| Mar 31, 2022 | 62,000.00 |
| Mar 31, 2022 | 62,000.00 |
| Dec 31, 2021 | -62,000.00 |
| Dec 31, 2021 | -62,000.00 |
| Sep 30, 2021 | 33,000.00 |
| Sep 30, 2021 | 33,000.00 |
| Jun 30, 2021 | 22,000.00 |
| Jun 30, 2021 | 22,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 1,953.00 |
| Dec 31, 2020 | 1,953.00 |
| Sep 30, 2020 | 2,275.00 |
| Sep 30, 2020 | 2,275.00 |
| Jun 30, 2020 | 3,308.00 |
| Jun 30, 2020 | 3,308.00 |
| Mar 31, 2020 | 1,885.00 |
| Mar 31, 2020 | 1,885.00 |
| Sep 30, 2019 | 756.00 |
| Sep 30, 2019 | 756.00 |
| Jun 30, 2019 | 748.00 |
| Jun 30, 2019 | 748.00 |
| Mar 31, 2019 | 740.00 |
| Mar 31, 2019 | 740.00 |
| Dec 31, 2018 | 127,353.00 |
| Dec 31, 2018 | 127,353.00 |
| Sep 30, 2018 | 166,946.00 |
| Sep 30, 2018 | 166,946.00 |
| Jun 30, 2018 | 1,921.00 |
| Jun 30, 2018 | 1,921.00 |
| Mar 31, 2018 | 870.00 |
| Mar 31, 2018 | 870.00 |
| Dec 31, 2017 | 2,036.00 |
| Dec 31, 2017 | 2,036.00 |
| Sep 30, 2017 | 2,344.00 |
| Sep 30, 2017 | 2,344.00 |
| Jun 30, 2017 | 97,156.00 |
| Jun 30, 2017 | 97,156.00 |
| Mar 31, 2017 | 60,603.00 |
| Mar 31, 2017 | 60,603.00 |
| Dec 31, 2016 | 9,641.00 |
| Dec 31, 2016 | 9,641.00 |
| Sep 30, 2016 | 9,408.00 |
| Sep 30, 2016 | 9,408.00 |
| Jun 30, 2016 | 9,618.00 |
| Jun 30, 2016 | 9,618.00 |
| Mar 31, 2016 | 1,050.00 |
| Mar 31, 2016 | 1,050.00 |
| Dec 31, 2015 | 6,089.00 |
| Dec 31, 2015 | 6,089.00 |
| Sep 30, 2015 | 9,888.00 |
| Sep 30, 2015 | 9,888.00 |
| Jun 30, 2015 | 13,279.00 |
| Jun 30, 2015 | 13,279.00 |
| Mar 31, 2015 | 25,325.00 |
| Mar 31, 2015 | 25,325.00 |
| Dec 31, 2014 | 37,043.00 |
| Dec 31, 2014 | 37,043.00 |
| Sep 30, 2014 | 46,930.00 |
| Sep 30, 2014 | 46,930.00 |
| Jun 30, 2014 | 56,554.00 |
| Jun 30, 2014 | 56,554.00 |
| Dec 31, 2013 | 77,071.00 |
| Dec 31, 2013 | 77,071.00 |
| Sep 30, 2013 | 89,817.00 |
| Sep 30, 2013 | 89,817.00 |
| Jun 30, 2013 | 100,027.00 |
| Jun 30, 2013 | 100,027.00 |
| Mar 31, 2013 | 99,791.00 |
| Mar 31, 2013 | 99,791.00 |
| Dec 31, 2012 | 115,651.00 |
| Dec 31, 2012 | 115,651.00 |
| Sep 30, 2012 | 112,529.00 |
| Sep 30, 2012 | 112,529.00 |
| Jun 30, 2012 | 111,353.00 |
| Jun 30, 2012 | 111,353.00 |
| Mar 31, 2012 | 3,028.00 |
| Mar 31, 2012 | 3,028.00 |
| Dec 31, 2011 | 14,033.00 |
| Dec 31, 2011 | 14,033.00 |
| Sep 30, 2011 | 9,932.00 |
| Sep 30, 2011 | 9,932.00 |
| Jun 30, 2011 | 15,173.00 |
| Jun 30, 2011 | 15,173.00 |
| Mar 31, 2011 | 15,435.00 |
| Mar 31, 2011 | 15,435.00 |
| Dec 31, 2010 | 3.12 Mn |
| Dec 31, 2010 | 3.12 Mn |
| Sep 30, 2010 | 946,023.00 |
| Sep 30, 2010 | 946,023.00 |
| Jun 30, 2010 | 921,465.00 |
| Jun 30, 2010 | 921,465.00 |